Documentos de Académico
Documentos de Profesional
Documentos de Cultura
Regenerative medicine?
Market Opportunities for Regenerative
Medicine
Government Policies Around The Globe
Conclusion
What is Regenerative
Medicine?
Regenerative medicine is the process of
creating living, functional tissues to
repair or replace tissue or organ
function lost due to age, disease,
damage, or congenital defects
Holds the promise of regenerating
damaged tissues and organs in the
body by stimulating previously
irreparable organs to heal themselves
B re a s t
V a lv e
L iv e r
V e sse ls
N e rv e
K id n e y
U re te r
B la d d e r
B one
O th e r g e n ito u rin a ry
S k in
C a rtila g e
Neo-bladder
A Model of Regenerative Medicine
A surgeon takes a Scientists isolate The isolated cells The cultured cells are
small, full- urothelial and smooth are cultured properly seeded onto a
thickness biopsy muscle cells that are separately until biodegradable scaffold
from the patient’s capable of there are a shaped like a bladder.
bladder. regeneration. sufficient quantity.
The biodegradable
scaffold dissolves
and is eliminated The body uses the The neo-bladder Scientists ensure that
from the body, neo-bladder construct is the cells attach and grow
leaving a construct to implanted by the properly throughout the
functioning bladder regenerate and surgeon using scaffold. After about 8
made only of the integrate new standard surgical weeks, the neo-bladder
patient’s own newly tissue, restoring techniques. construct is returned to
regenerated tissue. the bladder’s the surgeon for
functionality. implantation.
Why do we need
Regenerative
Medicine?
Need of Regenerative
Medicine
Opportunities for
Regenerative
Medicine
Building an Industry
> 350 Private or Public corporations in EU,
Asia, and US developing regenerative
medical products
Small/large molecule, scaffold, cell, combination
Financials
>$5B Market Capitalization (US)
~33% of Venture Capital’s
In India
S o u rce : M in t A u g u st 4 , 2 0 0 9
Exploration In India
S o u rce : M in t A u g u st 4 , 2 0 0 9
Selected Examples of
Building an Industry
1996: Integra's Artificial Skin approved by the FDA
Cell based/natural scaffold product
1997: Genzyme’s Carticel approved by FDA.
Cell based/scaffold free product
1998: Organogenesis’ Apligraf Skin Equivalent approved by FDA
Claim: "first manufactured living human organ"
1998: DePuy’s Restore Orthobiologic Soft Tissue Implant approved
by FDA
Scaffold based/cell free product
2006: Osiris’s PROCHYMAL™ Fast-Track by FDA/Orphan status by
EMEA
Cell based/scaffold free product
2006: Tengion’s neo-bladder Phase II IND accepted by FDA.
Cell based/synthetic scaffold product
Anticipated Industry
Revenue Growth
S o u rce – C a p e g e m in i re p o rt